516 related articles for article (PubMed ID: 8201382)
1. Antibody targeting in metastatic colon cancer: a phase I study of monoclonal antibody F19 against a cell-surface protein of reactive tumor stromal fibroblasts.
Welt S; Divgi CR; Scott AM; Garin-Chesa P; Finn RD; Graham M; Carswell EA; Cohen A; Larson SM; Old LJ
J Clin Oncol; 1994 Jun; 12(6):1193-203. PubMed ID: 8201382
[TBL] [Abstract][Full Text] [Related]
2. Biokinetics of a F(ab')3 iodine-131 labeled antigen binding construct (Mab 35) directed against CEA in patients with colorectal carcinoma.
Storto G; Buchegger F; Waibel R; Kuenzi G; Offord RE; Schubiger PA; Gillet M; Delaloye AB
Cancer Biother Radiopharm; 2001 Oct; 16(5):371-9. PubMed ID: 11776754
[TBL] [Abstract][Full Text] [Related]
3. Quantitative analysis of antibody localization in human metastatic colon cancer: a phase I study of monoclonal antibody A33.
Welt S; Divgi CR; Real FX; Yeh SD; Garin-Chesa P; Finstad CL; Sakamoto J; Cohen A; Sigurdson ER; Kemeny N
J Clin Oncol; 1990 Nov; 8(11):1894-906. PubMed ID: 2230877
[TBL] [Abstract][Full Text] [Related]
4. Population pharmacokinetics of antifibroblast activation protein monoclonal antibody F19 in cancer patients.
Tanswell P; Garin-Chesa P; Rettig WJ; Welt S; Divgi CR; Casper ES; Finn RD; Larson SM; Old LJ; Scott AM
Br J Clin Pharmacol; 2001 Feb; 51(2):177-80. PubMed ID: 11259992
[TBL] [Abstract][Full Text] [Related]
5. Dose escalation trial of indium-111-labeled anti-carcinoembryonic antigen chimeric monoclonal antibody (chimeric T84.66) in presurgical colorectal cancer patients.
Wong JY; Chu DZ; Yamauchi D; Odom-Maryon TL; Williams LE; Liu A; Esteban JM; Wu AM; Primus FJ; Beatty JD; Shively JE; Raubitschek AA
J Nucl Med; 1998 Dec; 39(12):2097-104. PubMed ID: 9867150
[TBL] [Abstract][Full Text] [Related]
6. Fibroblast activation protein: purification, epitope mapping and induction by growth factors.
Rettig WJ; Su SL; Fortunato SR; Scanlan MJ; Raj BK; Garin-Chesa P; Healey JH; Old LJ
Int J Cancer; 1994 Aug; 58(3):385-92. PubMed ID: 7519584
[TBL] [Abstract][Full Text] [Related]
7. Antibody localization in human renal cell carcinoma: a phase I study of monoclonal antibody G250.
Oosterwijk E; Bander NH; Divgi CR; Welt S; Wakka JC; Finn RD; Carswell EA; Larson SM; Warnaar SO; Fleuren GJ
J Clin Oncol; 1993 Apr; 11(4):738-50. PubMed ID: 8478666
[TBL] [Abstract][Full Text] [Related]
8. Human antibody derivatives against the fibroblast activation protein for tumor stroma targeting of carcinomas.
Mersmann M; Schmidt A; Rippmann JF; Wüest T; Brocks B; Rettig WJ; Garin-Chesa P; Pfizenmaier K; Moosmayer D
Int J Cancer; 2001 Apr; 92(2):240-8. PubMed ID: 11291052
[TBL] [Abstract][Full Text] [Related]
9. Complementation of intracavitary and intravenous administration of a monoclonal antibody (B72.3) in patients with carcinoma.
Colcher D; Esteban J; Carrasquillo JA; Sugarbaker P; Reynolds JC; Bryant G; Larson SM; Schlom J
Cancer Res; 1987 Aug; 47(15):4218-24. PubMed ID: 3607761
[TBL] [Abstract][Full Text] [Related]
10. Intraoperative detection of occult colon cancer micrometastases using 125 I-radiolabled monoclonal antibody CC49.
Cote RJ; Houchens DP; Hitchcock CL; Saad AD; Nines RG; Greenson JK; Schneebaum S; Arnold MW; Martin EW
Cancer; 1996 Feb; 77(4):613-20. PubMed ID: 8616751
[TBL] [Abstract][Full Text] [Related]
11. Fibroblast activation protein: differential expression and serine protease activity in reactive stromal fibroblasts of melanocytic skin tumors.
Huber MA; Kraut N; Park JE; Schubert RD; Rettig WJ; Peter RU; Garin-Chesa P
J Invest Dermatol; 2003 Feb; 120(2):182-8. PubMed ID: 12542520
[TBL] [Abstract][Full Text] [Related]
12. Clinical implications of fibroblast activation protein in patients with colon cancer.
Henry LR; Lee HO; Lee JS; Klein-Szanto A; Watts P; Ross EA; Chen WT; Cheng JD
Clin Cancer Res; 2007 Mar; 13(6):1736-41. PubMed ID: 17363526
[TBL] [Abstract][Full Text] [Related]
13. A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer.
Scott AM; Wiseman G; Welt S; Adjei A; Lee FT; Hopkins W; Divgi CR; Hanson LH; Mitchell P; Gansen DN; Larson SM; Ingle JN; Hoffman EW; Tanswell P; Ritter G; Cohen LS; Bette P; Arvay L; Amelsberg A; Vlock D; Rettig WJ; Old LJ
Clin Cancer Res; 2003 May; 9(5):1639-47. PubMed ID: 12738716
[TBL] [Abstract][Full Text] [Related]
14. Intratumoral distribution of radiolabeled antibody and radioimmunotherapy in experimental liver metastases model of nude mouse.
Sato N; Saga T; Sakahara H; Yao Z; Nakamoto Y; Zhang M; Kuroki M; Matsuoka Y; Iida Y; Konishi J
J Nucl Med; 1999 Apr; 40(4):685-92. PubMed ID: 10210230
[TBL] [Abstract][Full Text] [Related]
15. Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers.
Garin-Chesa P; Old LJ; Rettig WJ
Proc Natl Acad Sci U S A; 1990 Sep; 87(18):7235-9. PubMed ID: 2402505
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and tumor targeting of 131I-labeled F(ab')2 fragments of the chimeric monoclonal antibody G250: preclinical and clinical pilot studies.
Brouwers A; Mulders P; Oosterwijk E; Buijs W; Corstens F; Boerman O; Oyen W
Cancer Biother Radiopharm; 2004 Aug; 19(4):466-77. PubMed ID: 15453961
[TBL] [Abstract][Full Text] [Related]
17. Preselection of patients with high TAG-72 antigen expression leads to targeting of 94% of known metastatic tumor sites with monoclonal antibody I-131-CC49.
Kostakoglu L; Divgi CR; Hilton S; Cordon-Cardo C; Scott AM; Kalaigian H; Finn RD; Schlom J; Larson SM
Cancer Invest; 1994; 12(6):551-8. PubMed ID: 7994589
[TBL] [Abstract][Full Text] [Related]
18. Radioimmunoguided surgery.
Veroux G; Nicosia AS; Veroux P; Cardillo P; Veroux M; Amodeo C
Hepatogastroenterology; 1999; 46(30):3099-108. PubMed ID: 10626169
[TBL] [Abstract][Full Text] [Related]
19. Pilot radioimmunotherapy trial with 131I-labeled murine monoclonal antibody CC49 and deoxyspergualin in metastatic colon carcinoma.
Divgi CR; Scott AM; Gulec S; Broussard EK; Levy N; Young C; Capitelli P; Daghighian F; Williams JM; Finn RD
Clin Cancer Res; 1995 Dec; 1(12):1503-10. PubMed ID: 9815950
[TBL] [Abstract][Full Text] [Related]
20. Regulation and heteromeric structure of the fibroblast activation protein in normal and transformed cells of mesenchymal and neuroectodermal origin.
Rettig WJ; Garin-Chesa P; Healey JH; Su SL; Ozer HL; Schwab M; Albino AP; Old LJ
Cancer Res; 1993 Jul; 53(14):3327-35. PubMed ID: 8391923
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
